World's Best Scientists 2026 revealed!
Wilson H. Miller

Wilson H. Miller

D-Index & Metrics

Medicine

D-Index
91
Citations
54470
World Ranking
11502
National Ranking
464

Wilson H. Miller publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Wilson H. Miller sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 370 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Wilson H. Miller D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Wilson H. Miller sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Wilson H. Miller is affiliated with McGill University in Canada and has contributed extensively to the fields of Medicine, particularly within Oncology and Molecular Biology. Their research spans a variety of subfields including Immunology, Pulmonary and Respiratory Medicine, and Pathology and Forensic Medicine, reflecting a multidisciplinary approach to biomedical science.

Their body of work is notably concentrated on topics such as Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Genetic factors in colorectal cancer, Colorectal Cancer Treatments and Studies, Immunotherapy and Immune Responses, and Immune Cell Function and Interaction.

Wilson H. Miller's research has appeared in a range of journals, with frequent publications in the Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), Annals of Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. These venues highlight their focus on clinical and translational cancer research and immunotherapy.

Recent notable papers authored or co-authored by Wilson H. Miller include:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future (2020, Current Oncology)
  • Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022, Journal of Clinical Oncology)
  • Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022, Annals of Oncology)
  • Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial (2023, Nature Medicine)

Wilson H. Miller has collaborated frequently with a group of co-authors, which includes Sonia V. del Rincón, Christophe Gonçalves, Fan Huang, Natascha Gagnon, and Arielle Elkrief.

Best Publications

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

    A. Kakizuka;W.H. Miller;K. Umesono;K. Umesono;R.P. Warrell

  • Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

    Raymond P. Warrell;Stanley R. Frankel;Wilson H. Miller;David A. Scheinberg

  • Role of the histone deacetylase complex in acute promyelocytic leukaemia

    Richard J. Lin;Richard J. Lin;Richard J. Lin;Laszlo Nagy;Laszlo Nagy;Satoshi Inoue;Wenlin Shao

  • Mechanisms of action of arsenic trioxide.

    Wilson H. Miller;Hyman M. Schipper;Janet S. Lee;Jack Singer

  • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : I. As2O3 exerts dose-dependent dual effects on APL cells

    Guo-Qiang Chen;Xue-Geng Shi;Wei Tang;Shu-Min Xiong

  • A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein

    Jacqueline A. Dyck;Jacqueline A. Dyck;Gerd G. Maul;Wilson H. Miller;J.Don Chen

  • A review of cancer immunotherapy: from the past, to the present, to the future.

    K. Esfahani;L. Roudaia;N. Buhlaiga;S.V. Del Rincon

  • Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

    Josephia Muindi;Stanley R. Frankel;Wilson H. Miller;Ann Jakubowski

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

    Jose Baselga;Larry Norton;Hideo Masui;Atanasio Pandiella

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

    Jordi Rodon;Jean Charles Soria;Raanan Berger;Wilson H. Miller

  • Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

    L.J. Hoffer;M. Levine;S. Assouline;D. Melnychuk

  • Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells

    W. Shao;M. Fanelli;F. F. Ferrara;R. Riccioni

Frequent Co-Authors

Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Georgina V. Long
Georgina V. Long University of Sydney
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Axel Hauschild
Axel Hauschild Kiel University
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Paul Lorigan
Paul Lorigan University of Manchester
Samuel Waxman
Samuel Waxman Icahn School of Medicine at Mount Sinai
Hyman M. Schipper
Hyman M. Schipper McGill University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For aspiring medical professionals looking to accelerate their education or career transition, online programs offer flexible pathways to a variety of in-demand roles. Many students pursuing Medicine in the USA consider alternative health degrees to gain experience or advance more quickly within the healthcare field. These flexible online qualifications can be an excellent stepping stone or complement to a traditional medical education.

Those interested in advanced nursing roles may want to explore the short dnp programs which enable practitioners to complete their doctorate in nursing practice at a faster pace. If balancing work and study is a concern, you can also review the easiest dnp programs designed for students seeking manageable coursework without sacrificing educational quality.

For quicker entry into the nursing workforce, fast track medical lpn programs allow you to become a Licensed Practical Nurse in less time. Additionally, for those interested in mental health, the psych np online programs can open the door to specialized nurse practitioner roles with both speed and convenience.

Best Scientists Citing Wilson H. Miller

Trending Scientists

Recently Published Articles